Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.041
Buy
RSI(14)
57.204
Neutral
STOCH(KDJ)(9,3,3)
51.039
Buy
ATR(14)
0.230
High Vlolatility
CCI(14)
65.240
Neutral
Williams %R
42.029
Buy
TRIX(12,20)
0.240
Sell
StochRSI(14)
96.426
Overbought
Arbutus Biopharma Corp
ABUS4.780USD
-0.010-0.21%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
917.54MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Arbutus Biopharma Corp
Currency: USD Updated: 2025-12-26Key Insights
Arbutus Biopharma Corp's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 73/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.67.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Arbutus Biopharma Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.667
Target Price
+25.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Arbutus Biopharma Corp Highlights
StrengthsRisks
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.17M.
Undervalued
The company’s latest PE is -21.66, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 120.46M shares, increasing 0.01% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 14.77K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Arbutus Biopharma Corp is 6.05, ranking 306/404 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 529.00K, representing a year-over-year decrease of 60.49%, while its net profit experienced a year-over-year decrease of 60.73%.
Score
Financials
7.57
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.30
Operational Efficiency
2.83
Growth Potential
5.46
Shareholder Returns
7.07
Arbutus Biopharma Corp's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Arbutus Biopharma Corp is 6.88, ranking 213/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.66, which is -83.27% below the recent high of -3.62 and -3.56% above the recent low of -22.43.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 73/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Arbutus Biopharma Corp is 8.67, ranking 72/404 in the Biotechnology & Medical Research industry. The average price target for Arbutus Biopharma Corp is 5.00, with a high of 7.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
5.667
Target Price
+25.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Arbutus Biopharma Corp
ABUS
3
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Arbutus Biopharma Corp is 9.08, ranking 52/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.21 and the support level at 4.22, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.680
Buy
MA10
4.683
Buy
MA20
4.556
Buy
MA50
4.520
Buy
MA100
4.280
Buy
MA200
3.790
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Arbutus Biopharma Corp is 5.00, ranking 146/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.27%, representing a quarter-over-quarter decrease of 0.85%. The largest institutional shareholder is The Vanguard, holding a total of 8.96M shares, representing 4.66% of shares outstanding, with 0.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Roivant Sciences Ltd.
Morgan Stanley Investment Management Inc. (US)
Whitefort Capital Management, LP
BlackRock Institutional Trust Company, N.A.
Two Seas Capital LP
Adage Capital Management, L.P.
State Street Investment Management (US)
Geode Capital Management, L.L.C.
Adar1 Capital Management LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Arbutus Biopharma Corp is 5.40, ranking 51/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.71
VaR
+5.00%
240-Day Maximum Drawdown
+19.78%
240-Day Volatility
+50.92%
Return
Best Daily Return
60 days
+6.55%
120 days
+6.70%
5 years
+44.06%
Worst Daily Return
60 days
-7.27%
120 days
-8.98%
5 years
-12.46%
Sharpe Ratio
60 days
+0.69
120 days
+2.18
5 years
+0.36
Risk Assessment
Maximum Drawdown
240 days
+19.78%
3 years
+45.48%
5 years
+63.42%
Return-to-Drawdown Ratio
240 days
+2.16
3 years
+0.57
5 years
+0.10
Skewness
240 days
+0.05
3 years
+0.37
5 years
+1.90
Volatility
Realised Volatility
240 days
+50.92%
5 years
+64.65%
Standardised True Range
240 days
+3.63%
5 years
+3.31%
Downside Risk-Adjusted Return
120 days
+343.76%
240 days
+343.76%
Maximum Daily Upside Volatility
60 days
+31.71%
Maximum Daily Downside Volatility
60 days
+28.76%
Liquidity
Average Turnover Rate
60 days
+0.41%
120 days
+0.46%
5 years
--
Turnover Deviation
20 days
-18.28%
60 days
-21.82%
120 days
-11.80%
Peer Comparison
Biotechnology & Medical Research
Arbutus Biopharma Corp
ABUS
7.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Arbutus Biopharma Corp?
The TradingKey Stock Score provides a comprehensive assessment of Arbutus Biopharma Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Arbutus Biopharma Corp’s performance and outlook.
How do we generate the financial health score of Arbutus Biopharma Corp?
To generate the financial health score of Arbutus Biopharma Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Arbutus Biopharma Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Arbutus Biopharma Corp.
How do we generate the company valuation score of Arbutus Biopharma Corp?
To generate the company valuation score of Arbutus Biopharma Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Arbutus Biopharma Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Arbutus Biopharma Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Arbutus Biopharma Corp.
How do we generate the earnings forecast score of Arbutus Biopharma Corp?
To calculate the earnings forecast score of Arbutus Biopharma Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Arbutus Biopharma Corp’s future.
How do we generate the price momentum score of Arbutus Biopharma Corp?
When generating the price momentum score for Arbutus Biopharma Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Arbutus Biopharma Corp’s prices. A higher score indicates a more stable short-term price trend for Arbutus Biopharma Corp.
How do we generate the institutional confidence score of Arbutus Biopharma Corp?
To generate the institutional confidence score of Arbutus Biopharma Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Arbutus Biopharma Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Arbutus Biopharma Corp.
How do we generate the risk management score of Arbutus Biopharma Corp?
To assess the risk management score of Arbutus Biopharma Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Arbutus Biopharma Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Arbutus Biopharma Corp.
